Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2025)

Zevra Therapeutics' Operating Leases history spans 7 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 61.36% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 61.36%, while the annual FY2025 figure was $1.3 million, 61.36% up from the prior year.
  • Operating Leases reached $1.3 million in Q4 2025 per ZVRA's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.7 million in Q3 2021 to a low of $456000.0 in Q4 2023.
  • Average Operating Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Operating Leases: crashed 46.91% in 2022, then soared 191.3% in 2025.
  • A 5-year view of Operating Leases shows it stood at $1.6 million in 2021, then plummeted by 46.91% to $843000.0 in 2022, then crashed by 45.91% to $456000.0 in 2023, then skyrocketed by 73.68% to $792000.0 in 2024, then skyrocketed by 61.36% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Operating Leases are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.1 million (Q2 2025).